Selective progesterone receptor modulators (SPRMs): Progesterone receptor action, mode of action on the endometrium and treatment options in gynaecological therapies. by Wagenfeld, Andrea et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Selective progesterone receptor modulators (SPRMs):
Progesterone receptor action, mode of action on the
endometrium and treatment options in gynaecological therapies.
Citation for published version:
Wagenfeld, A, Saunders, P, Whitaker, L & Critchley, H 2016, 'Selective progesterone receptor modulators
(SPRMs): Progesterone receptor action, mode of action on the endometrium and treatment options in
gynaecological therapies.', Expert Opinion on Therapeutic Targets.
https://doi.org/10.1080/14728222.2016.1180368
Digital Object Identifier (DOI):
10.1080/14728222.2016.1180368
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Expert Opinion on Therapeutic Targets
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=iett20
Download by: [The University of Edinburgh] Date: 17 May 2016, At: 03:33
Expert Opinion on Therapeutic Targets
ISSN: 1472-8222 (Print) 1744-7631 (Online) Journal homepage: http://www.tandfonline.com/loi/iett20
Selective progesterone receptor modulators
(SPRMs): progesterone receptor action, mode of
action on the endometrium and treatment options
in gynecological therapies
Andrea Wagenfeld, Philippa T.K. Saunders, Lucy Whitaker & Hilary O.D.
Critchley
To cite this article: Andrea Wagenfeld, Philippa T.K. Saunders, Lucy Whitaker & Hilary O.D.
Critchley (2016): Selective progesterone receptor modulators (SPRMs): progesterone receptor
action, mode of action on the endometrium and treatment options in gynecological therapies,
Expert Opinion on Therapeutic Targets, DOI: 10.1080/14728222.2016.1180368
To link to this article:  http://dx.doi.org/10.1080/14728222.2016.1180368
© 2016 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group
Accepted author version posted online: 03
May 2016.
Published online: 14 May 2016.
Submit your article to this journal 
Article views: 44
View related articles 
View Crossmark data
REVIEW
Selective progesterone receptor modulators (SPRMs): progesterone receptor action,
mode of action on the endometrium and treatment options in gynecological
therapies
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aBayer HealthCare, Drug Discovery, TRG Gynecological Therapies, Berlin, Germany; bMRC Centre for Inflammation Research, The University of
Edinburgh, Edinburgh, UK; cMRC Centre for Reproductive Health, The University of Edinburgh, Edinburgh, UK
ABSTRACT
Introduction: The progesterone receptor plays an essential role in uterine physiology and reproduction.
Selective progesterone receptor modulators (SPRMs) have emerged as a valuable treatment option for
hormone dependent conditions like uterine fibroids, which have a major impact on women’s quality of
life. SPRMs offer potential for longer term medical treatment and thereby patients may avoid surgical
intervention.
Areas covered: The authors have reviewed the functional role of the progesterone receptor and its
isoforms and their molecular mechanisms of action via genomic and non-genomic pathways. The
current knowledge of the interaction of the PR and different SPRMs tested in clinical trials has been
reviewed. The authors focused on pharmacological effects of selected SPRMs on the endometrium, their
anti-proliferative action, and their suppression of bleeding. Potential underlying molecular mechanisms
and the specific histological changes in the endometrium induced by SPRMs (PAEC; Progesterone
receptor modulator Associated Endometrial Changes) have been discussed. The clinical potential of this
compound class including its impact on quality of life has been covered.
Expert Opinion: Clinical studies indicate SPRMs hold promise for treatment of benign gynecological
complaints (fibroids, heavy menstrual bleeding; HMB). There however remains a knowledge gap
concerning mechanism of action.
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1. Introduction: the impact of progesterone and
uterine function
Progesterone is a steroid hormone that plays a key role in
development, differentiation, and normal functioning of
female reproduction-related target tissues including the
uterus (endometrium and myometrium), the ovary, and the
mammary gland as well as in the regulation of the hypotha-
lamic–pituitary–gonadal axis. Abnormal progesterone
responses are implicated in a wide spectrum of benign
human reproductive disorders, including fibroids, endometrio-
sis and adenomyosis, abnormal uterine bleeding (AUB; includ-
ing heavy menstrual bleeding [HMB]), and miscarriage.[1–4]
From the onset of puberty to menopause, progesterone is
mainly produced by the corpus luteum in the ovary with
smaller amounts secreted by the adrenal glands.
Actions of progesterone on the female reproductive system
are primarily mediated by progesterone receptors (PRs)
synthesized from a single gene (PR) and expressed as two
main protein isoforms (PR-A, PR-B).[5,6] Beyond its prominent
function in reproductive tract tissues, progesterone is also
involved in regulation of cellular functions in the central ner-
vous system [7] influencing reproductive behaviors.
Progesterone also plays an important role during pregnancy
and has striking impacts on the function of the breast.[8]
The uterine endometrium comprises of epithelial cells (lin-
ing the luminal surface and glands), stromal cells, immune
cells, and blood vessels and it is arranged in two morphologi-
cally and functionally distinct zones, the inner basal zone and
the outer functional zone with the latter being shed at men-
struation.[6,9] The human myometrium, localized between
endometrium and perimetrium, is a heterogeneous tissue
and can also be subdivided in two zones, namely the outer
myometrium and a functionally distinct inner myometrial layer
called the uterine junctional zone.[10,11] This ‘junctional’ zone
can be visualized with magnetic resonance imaging (MRI) but
is not histologically distinct. The myometrium is largely made
up of smooth muscle cells but also contains connective tissue,
blood vessels, and immune cells. The principal uterine cellular
targets for progesterone, expressing PR-A and PR-B, are the
epithelial and stromal/decidual cells in the endometrium
[12,13] and smooth muscle cells in the myometrium.[14]
During the menstrual cycle, the human endometrium
undergoes dynamic changes including proliferation, differen-
tiation, tissue breakdown, and shedding (menstruation) in
response to fluctuating peripheral concentrations of ovarian-
derived estrogen and progesterone. Estrogens, acting via their
cognate receptors, play a key role in modulating tissue func-
tion in the follicular (proliferative) phase by inducing epithelial
and stromal cell proliferation leading to a thickened functional
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zone. Estrogens also stimulate expression of PR, thus ensuring
progesterone responsiveness in the post-ovulatory luteal
(secretory) phase.[6] Estrogen levels decline after ovulation
[15,16] and rising concentrations of progesterone secreted
by the corpus luteum initiate a differentiation program char-
acterized by growth and coiling of the spiral arteries, secretory
transformation of the glands, an influx of distinct immune
cells, especially specialized uterine natural killer cells, and
transformation of the stromal fibroblasts (decidualization) in
preparation for blastocyst implantation.[17,18] Progesterone
induces genes that allow the endometrium to permit embryo
attachment and directly controls vascular permeability.[6,19]
2. PRs
2.1. Intracellular and membrane PR isoforms
The PR as a member of the nuclear hormone receptor super-
family is a ligand-dependent transcription factor [20,21] char-
acterized by structural motifs like the N-terminal A/B region, a
highly conserved DNA-binding domain (DBD), a hinge region,
and a C-terminal ligand-binding domain (LBD). The DBD is
composed of two conserved zinc fingers that distinguish
nuclear receptors from other DNA-binding proteins.
The PR-A and PR-B mRNA isoforms are both transcribed
from the same PR gene and the proteins they encode are
identical in their DNA-binding and ligand-binding properties;
it is likely that PR A/B homodimers and heterodimers exist.[22]
PR-B (116 kDa) differs from PR-A (94 kDa) only by an additional
stretch of 165 AA at the N-terminus of the protein. A marked
physiological difference is the action of PR-A as a trans-domi-
nant inhibitor of PR-B [23] and it even exerts this inhibitory
action onto other members of the NR superfamily including
ER, androgen receptor (AR), MRI, and GR.[24]
Differential recruitment of PR [25,26] and associated tran-
scriptional co-regulators to gene promoters are critical to
tissue selective impacts of progesterone (details see below)
for example, whereas in the uterus progesterone stimulates
growth of leiomyomas, it inhibits growth of the endome-
trium.[6]
The ratio of PR-A and -B expression varies from tissue to
tissue and is dependent on the hormonal status of the cell.[27]
In full thickness sections of the human uterus, parallel expres-
sion of ERα and PR can be detected using immunofluores-
cence (Figure 1; antibody for PR, recognizing both A and B
isoforms), demonstrating intense immunoexpression in gland-
ular epithelium at the start of the secretory phase following
induction during the follicular phase with subsequent down-
regulation in the mid-secretory phase. Whereas PR-A levels in
epithelial cells decline in late secretory phase, PR-B levels
remain constant, suggesting that this subtype may be
involved in the control of glandular secretion.[6] Studies to
assess the cellular localization of PR-A and PR-B have to be
interpreted with caution as they are technically limited due to
the common sequence of PR-A and PR-B and the abundance
of PR-A and its relative level to PR-B may only be determined
in a semiquantitative manner at best. PR-A appears to be
predominant subtype in the stromal cells, with a less obvious
Article highlights
● Abnormal progesterone responses are implicated in a wide spectrum
of benign human reproductive disorders, including abnormal uterine
bleeding (AUB; including heavy menstrual bleeding [HMB]), fibroids
(leiomyomas) and endometriosis.
● Progesterone acting via its cognate receptors (PR-A, PR-B) plays a
central role in regulation of uterine function making PR an attractive
therapeutic target.
● Differential recruitment of PR and associated transcriptional co-reg-
ulators to gene promoters are critical to tissue selective impacts of
progesterone, for example, whereas it inhibits growth of the endo-
metrium it stimulates growth of fibroids (leiomyomas).
● Selective progesterone receptor modulators (SPRMs) represent a new
class of synthetic ligands, which can exert agonist, antagonist or
mixed effects on various progesterone target tissues.
● Administration of all family members of the SPRM class of compound
have been found to date to be accompanied with morphological
changes within the endometrium described as progesterone receptor
modulator associated endometrial changes (PAEC). These histological
changes are recognized as a distinct histological entity.
● Whilst PAEC are now well described and appear reversible, the
mechanisms by which these develop are poorly understood.
This box summarizes key points contained in the article.
Figure 1. Immunolocalisation of ERα and PR in full thickness sections of human
endometrium.
Images shown from four samples of uterine tissue recovered during the early (ES) or
mid (MS) secretory phases of the cycle: each section represents the full thickness of
the uterine wall with the lumen at the top andmyometrium at the bottom. Sections
were co-stained for ERα (red) and PR (green) using standard protocols [32] for clarity
the images recorded in the different channels (red, green) are shown side-by-side
rather than overlaid. Note that during the ES there is intense immunopositive
staining for both ERα and PR-A in the glandular epithelium in both the functional
(arrows) and basal (white asterisks) layers. During the MS immunoexpression in the
epithelium is down-regulated but expression of PR in stromal fibroblasts is main-
tained (green asterisks). Full color available online.
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decline in expression during the luteal phase than in the
epithelium, which might reflect the need for prolonged pro-
gesterone PR-A signaling in this compartment to support the
establishment of pregnancy.[12,28] Both receptors have been
detected in leiomyoma (fibroid) tissue [29] and seem to be
increased in leiomyoma compared with normal myometrium
from the same patients.[30,31]
To delineate the individual roles of the receptor subtypes in
vivo, PR isoform-specific knockout (KO) mice have been gen-
erated.[33,34] In these studies, female mice with a global
ablation of both receptor subtypes failed to reproduce due
to defects in both ovulation and implantation.[33,34] Specific
ablation of PR-A alone also resulted in severe abnormalities in
ovarian and uterine function leading to female infertility.[35]
In contrast, PR-B-specific KO mice had normal ovarian and
uterine responses to progesterone but exhibited reduced
mammary ductal morphogenesis and alveologenesis during
pregnancy. Both PR subtypes of receptor appear to mediate
anti-inflammatory actions of progesterone on the endome-
trium.[36] Notably, both subtypes mediate progesterone-
dependent responses through activation of different subsets
of genes with those regulated by PR-A being both necessary
and sufficient for reproductive fertility functions, while PR-B-
dependent gene activation, at least in mice, plays a key role in
mammary development.[24,36] Although some additional var-
iant PR mRNAs (PR-C, -M, -S, and -T) have been described, a
recent comprehensive protein analysis did not support their
translation in vivo.[37]
In addition to the PR receptors that are members of the
superfamily of transcription factors, a membrane-bound PR
(mPR) first described in fish has been implicated in rapid
non-genomic actions (see below) of progesterone.[38,39]
Upon progesterone binding, mPRs may influence the activity
of several signaling pathways, including mobilization of intra-
cellular Ca2+, activation of mitogen-activated protein kinase
(MAPK) cascades, and inhibition of cAMP production.[40] The
physiologic relevance of the membrane PR is still unclear since
their capacity to bind progesterone is relatively low compared
to nuclear PRs and some studies could not even detect evi-
dence of activation by progesterone.[41]
2.2. Genomic and non-genomic activation of PR
In the reproductive tract, it is likely that progesterone exerts its
effects via both genomic and non-genomic actions mediated
via PR-A or PR-B that subsequently converge to produce tis-
sue- and cell-specific responses.[42] In the ‘classical’ genomic
mode of action binding of a ligand within the LBD, conforma-
tional changes are initiated, chaperone proteins dissociate and
the PR translocates to the nucleus. Within the nucleus, ligand-
bound PRs interact with the transcriptional machinery and
bind as homo- or heterodimers to specific cis-acting PR
response elements (PRE), typically located in the promoter
regions of target genes. Robust, specific modulation of gene
transcription, however, requires recruitment of additional co-
regulatory proteins to a transcription complex that includes
the DNA-bound receptor. The different co-regulatory factors
are generally considered to act to enhance transcription
(coactivators) or to decrease the level of transcriptional activa-
tion (corepressors).[26] Over 300 co-regulators are reported to
interact with PR, and it is the tissue-specific expression of the
factors that orchestrates the impact of progesterone on
expression of different sets of genes within target tissues.[43]
It is now well established that binding of agonists or
antagonists to distinct amino acid residues within the LBD of
PR alters the conformation of the receptor protein resulting in
recruitment of differing type(s) of co-regulatory proteins into
the transcription complex. For example, following binding of
agonists, coactivators capable of modifying core histone pro-
tein side chains via acetylation or methylation are recruited
and the resultant change in histone proteins facilitates access
of the transcription machinery. PR coactivators include mem-
bers of the steroid receptor coactivator (SRC) family (SRC-1–3)
and receptor-interacting protein 140.[44] The importance of
the SRC PR interactions has been elucidated by studies in KO
mice demonstrating that steroid receptor coactivator-1 (SRC-1)
is the primary coactivator of PR in the uterus but SRC-3 is
important in the mammary gland.[45] Lately, a new class of PR
modulators the Kruppel-like factors (KLFs) [46] have been
described and the absence of some KLFs in distinct patholo-
gies (e.g. KLF9 and KLF11 in endometriosis and leiomyoma)
suggests roles for multiple KLFs in maintaining homeostasis in
female reproductive tissues.
On the other hand, PR can also interact with corepressors
and this generally occurs in the presence of ligands like mife-
pristone that act as antagonists. Crystal structures have shown
binding of the nuclear receptor corepressor (NCoR), and the
silencing mediator of retinoic acid and thyroid hormone
receptor (SMRT) to both PR-A and PR-B in the presence of
asoprisnil, a synthetic PR receptor modulator that is a mixed
agonist/antagonist and downregulates expression of PR in
endometrium.[47,48] In the human endometrium, the expres-
sion of both PR isoforms and their corepressors (NCoR and
SMRT) has been observed [28,49] and is modulated over the
course of the menstrual cycle in a compartment-specific man-
ner [49] demonstrating the potential for stage-dependent
gene repression.
Finally, additional cell-specific impacts of ligand-activated
PR may be determined by the co-recruitment of coactivators
and a number of additional transcription factors also
expressed in endometrium some of which appear to play a
key role in decidualization of stromal cells in preparation for
establishment of pregnancy. Examples include members of
the forkhead-box O (FOXO) protein family (FOXO1, FOXO3a),
signal transducer, and activator of transcription (STAT5) and
CCAAT enhancer-binding protein (C/EBPβ).[50]
Ligand-bound nuclear PR receptors can also be transcrip-
tionally active at endogenous promoters lacking a canonical
PRE. Transcription of these genes seems to be facilitated
through nuclear protein–protein interactions with other
DNA-binding transcription factors such as NFκB,[51] SP1, and
AP-1.[52] Levels of gene transcription can also be modulated
by post-translational modification of PRs primarily through
N-terminal phosphorylation, acetylation, SUMOylation, and
ubiquitination.[53,54] These modifications alter PRs trafficking,
transcriptional activity, and target-gene selectivity.[55] Studies
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in cancer cells have shown that modifications involve phos-
phorylation through mitogenic protein kinases, CDK2, CK2, or
MAPK of the receptor.[56] PR has been shown to trigger Src-
dependent phosphorylation signaling cascades like prolifera-
tive Ras/Raf/MEKK/MAK kinase pathway.[7] The relevance for
uterine tissue dysfunction remains poorly understood.
In addition to its direct effect on transcription, progester-
one has been identified to influence the activity of many other
signaling pathways by non-genomic (extranuclear) mechan-
isms in the cytoplasm.[57] These rapid non-genomic effects
triggered by progesterone binding to membrane-bound
receptors exhibit an onset within seconds to minutes (see
Table 1) and are insensitive to transcription or translation
inhibitors. A detailed description of non-genomic progester-
one effects in different target tissues and potential membrane
receptors involved has been reviewed by Gellersen et al.[42]
Finally, the distinction between the rapid non-genomic
kinase activation and genomic actions has become less certain.
For example, results using breast cancer cells have demon-
strated activated kinases can be recruited together with the
phosphorylated nuclear PR into an integrated PRE-containing
promotor.[66] According to this model, rapid signaling may be
a concurrent pathway integrated into the activation of the
transcriptional machinery by nuclear PR,[67] but further studies
are required to validate this in nonmalignant cells.
3. Selective progesterone receptor modulators
3.1. Modulation of PR activity by selective progesterone
receptor modulators
Selective progesterone receptor modulators (SPRMs) represent
a new class of synthetic steroids, which can exert agonist,
antagonist, or mixed effects on various progesterone target
tissues in vivo upon PR binding [68] (see Figure 2). They have
many potential clinical applications in female reproduction
and gynecological therapies like uterine fibroids but also in
the treatment of some tumors.[57]
Table 1. Non-genomic signaling pathways reported to be triggered by progesterone.
Involved signaling pathways
SRC/ERK/MAPK pathway
● Delayed P-dependent neuroprotection mediated by Src-ERK signaling
● Cyclin D1 gene induction by PR activation of the Src/MAPK pathway
● Rapid activation of Src/Erk1/2 and PI3K/Akt pathways in breast cancer and endometrial stromal cells via
crosstalk between PR and ERα/β
Boonyaratanakornkit et al.,[58] Cai et al.,[59] Ballare
et al.,[60] Mani et al. [7]
PI3K/Akt/NFκB pathway
Stimulation mPR by P activates the PI3K/Akt/NFκB pathway resulting in (1) inactivation of FOXO
transcriptional activity and (2) downregulation of miR-29c which triggers KLF4
Vares et al. [61]
MEK1/2 and PKA
Activation of macrophages by P via mPR causes pro-inflammatory shift in mRNA expression profile and
significant upregulation of cyclooxygenase 2, Il1B, and TNF and downregulation of mPRα
MEK1/2 and PKA are involved in mPR signaling
Lu et al.,[62] Mani et al. [7]
PKC
Rapid increase in basal PKC activity in VMN by P
Balasubramanian et al. [63]
Calcium and calmodulin kinase II
P-activation of CaMKII basal activity in VMN
Balasubramanian et al. [64]
PKG
● PgRMC1 shown to mediate rapid progestin actions in various tissues (including brain) by potential
activation of PKG
Bashour et al. [65]
PKA: Protein kinase A; PKC: protein kinase C; VMN: ventromedial nucleus; PKG: protein kinase G; PgRMC1: progesterone receptor membrane component 1.
Figure 2. Structure of common SPRMs.
Chemical structures of selective progesterone receptor modulators (SPRMs) in current clinical use or which have been in clinical development.
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X-ray crystal structures of the PR bound to SPRM ligands
revealed that the mode of binding differs between different
molecules and depends on the agonistic or antagonistic nat-
ure of the interaction.[69] The resulting effect on target genes
appears to depend both on the cell type and availability of
different co-regulators [70] also confirmed by evaluation of
protein–protein interactions with PR and SPRMs.[71]
The first and one of the most widely used SPRMs with
mixed agonistic/antagonistic properties and tissue-specific
effects is mifepristone (RU486). Wardell et al. described the
involvement of the amino-terminal domain of the PR and the
phosphorylation of a serine for the partial agonist features of
mifepristone.[72]
With an in vitro chromatin transcription system that reca-
pitulates PR-mediated transcription in vivo, Liu et al. [44]
have determined the molecular basis by which mifepristone
regulates transcription in a cell-type-specific manner.
Specifically, agonist-bound PR interacts only with coactiva-
tors such as SRC-1, whereas mifepristone-bound PR binds to
both the coactivator SRC-1 and the corepressor silencing
mediator for retinoid and thyroid hormone receptor (SMRT)
so that the precise impact in different cell types may be
influenced by the relative availability/abundance of these
factors.
Afhuppe and colleagues [73] compared different SPRMs
and their ability of interaction with PR and co-regulators.
Mifepristone, onapristone, and lonaprisan (ZK230211) differ
in their induced interactions of PR with the NCoR. PR modu-
lators with marked PR agonistic activity demonstrate induced
interactions with the LX-H10 peptide (contains the LxxLL motif
of coactivators) similarly to the ones observed with R5020
(promegestrone), whereas SPRMs with antagonistic behavior
like lonaprisan do not show any recruitment of the LX-H10
peptide.[74] In contrast to mifepristone, asoprisnil mediates
the recruitment of coactivators to the PR in vitro. However,
none of these compounds has a progesterone-like ability to
oppose estrogen in the rat endometrium,[47] again demon-
strating the high degree of complexity of the system as a
whole.[70] There have been several recent reviews that pro-
vide informative summaries of the effects of SPRM administra-
tion.[75–77]
3.2. Impact of SPRMs upon leiomyoma growth and
endometrial morphology
The mechanisms of fibroid growth reduction have been
addressed in several in vitro studies but a clearer picture may
be expected in the near future when fibroid biopsies from the
different clinical studies using SPRMs are fully analyzed. So far,
there is strong evidence that SPRMs induce apoptosis through
activation of the tumor necrosis-related apoptosis-inducing
ligand (TRAIL) pathways.[78] Fibroids treated with ulipristal
acetate (UPA) revealed upregulation of caspase 3 and down-
regulation of BCL2.[79] Furthermore, ample evidence exists
that strong expression of extracellular matrix in fibroids is
reduced by SPRMs due to suppression of collagen synthesis
(type I and III) and modulation of extracellular matrix enzymes
like MMPs and TIMPs.[80]
An interesting aspect in the pathomechanism of fibroid
growth has recently been addressed by Bulun et al..[81] They
describe a paracrine pathway that may mediate progesterone-
derived growth of leiomyoma tissue. Treatment of mature
myometrial cells with estrogen and progesterone resulted in
secretion of wingless type (WNT) ligands, translocation of β-
catenin in neighboring leiomyoma stem-progenitor cells, and
activation of gene expression critical for fibroid growth and
proliferation. The importance of WNT/β-catenin signaling in
formation of leiomyoma-like tumors and fibrogenesis has
been shown in mice that express a constitutively active form
of β-catenin in mesenchymal cells of the uterus.[82]
In this context, it is noteworthy to mention that the med-
iator complex subunit 12 (MED12) gene, which has been pre-
viously demonstrated to regulate β-catenin/WNT signaling,
has mutations in exon 2 in nearly 70% of uterine leiomyo-
mas.[83] The role(s) for such signaling pathways in the endo-
metrium of women with fibroids has to date not been
determined.
The administration of all family members of the SPRM class
of compound has been found to date to be accompanied with
morphological changes within the endometrium described as
PR modulator-associated endometrial changes (PAEC).[84]
These histological changes are recognized as a distinct histo-
logical entity and should not be confused with endometrial
hyperplasia. SPRMs have been shown to induce a specific
endometrial antiproliferative effect and the endometrial
glandular epithelium shows reduced mitotic activity compared
to the proliferative phase. Furthermore, evidence is accumu-
lating that PAEC rapidly regress on cessation of treatment,
although the rate of regression can be variable.[85] Whilst
PAEC are now well described and appear reversible, the
mechanisms by which these develop are poorly understood.
UPA is a SPRM licensed in Europe for preoperative treat-
ment of moderate-to-severe symptoms of uterine fibroids in
adult women of reproductive age and also for intermittent
treatment of moderate-to-severe symptoms of uterine fibroids
in adult women of reproductive age.[86] In common with
other SPRMs, UPA significantly reduces menstrual bleeding
and fibroid volume.[85,87]
The mechanisms responsible for these effects remain
poorly understood. In keeping with other SPRMs, despite pro-
gesterone antagonism and maintenance of circulating estra-
diol levels, hyperplasia does not occur with any increased
frequency although extensive cystic glandular dilatation is
seen.[88,89] Although in vitro work describes antiproliferative
and proapoptotic effects on leiomyoma cells,[90] there are
only limited data on the effects of SPRMs upon human
endometrium.
Studies in nonhuman primates (macaques) have shown a
suppressive effect specifically upon the endometrium with a
reduction in proliferation markers and upregulation of the AR
consistent with the ‘class effect’ of other SPRMs.[91] In a long-
term oral toxicity study with UPA,[92] findings in the endome-
trium were similar to SPRM-associated endometrial changes
described in SPRM-treated women. No adverse effects were
observed that would raise concerns about potential prema-
lignancy. Detailed human in vivo data still remain limited to
small studies. Apoptosis indices are increased in the
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endometrium, but knowledge of impact upon proliferation
and sex steroid receptor expression to date are again limited.
Thus far, there have been no reports of cytological atypia
accompanying SPRM administration in the presence of a nor-
mal endometrial biopsy prior to drug therapy with SPRMs.
Administration of low-dose mifepristone (RU486; 2–5 mg) for
120 days was observed to reduce endometrial proliferation
markers.[93] Administration of another SPRM with mixed ago-
nist–antagonist activity, asoprisnil, had no reports of endome-
trial hyperplasia with administration limited to daily
administration for 12 weeks. Oral daily doses of both 10 or
25-mg asoprisnil had no impact on markers of endometrial
proliferation.
The discovery of the ‘endometrial antiproliferative effect’ of
SPRMs was an important milestone in their development. This
effect was initially observed in rabbit and primate endome-
trium. The finding of endometrial atrophy induced by the
SPRM class of compound was not anticipated. The compounds
were reported not to bind the estrogen receptor due to PR
antagonist activity and thus the endometrium would have
been expected to exhibit unopposed estrogenic effects and
yet functional antiestrogenic effects were reported. The
believed unique endometrial effects of SPRMs are specific to
menstruating primates such as Old World monkeys and
humans. Cynomolgus and rhesus macaques are good models,
as their endometrium is similar to the human with respect to
hormonal regulation and morphological changes during the
menstrual cycle. Studies in nonhuman primates have been
reported to show that SPRM administration in both spayed
and intact macaques induced endometrial atrophy with stro-
mal compaction and inhibited mitotic activity. These effects
were observed following administration of mifepristone
(RU486), ZK 230 211, and ZK 137 316.[94] Studies with ZK
137 316 in the rhesus monkey also showed a dose-dependent
degradation of the spiral arteries in the basal layer of the
endometrium. It is notable that these profound morphological
changes were observed in the presence of follicular phase
estrogen levels. This functional antiestrogenic effect appears
to be limited to the endometrium. The oviduct and vagina are
reported to be unaffected, thereby providing evidence for an
‘endometrial antiproliferative effect’ and provides support that
SPRMs may target the endometrium directly and this effect
may possibly be via the endometrial vasculature. Dosage of
SPRM administration may be important as some effects may
be dose-dependent.[94,95]
The SPRM, asoprisnil, suppresses endometrial bleeding
and administration has a striking histological effect on the
endometrial spiral arteries which develop an unusual
appearance as prominent aggregations due to abnormally
thick muscular walls.[96] When global endometrial gene
expression in asoprisnil-treated versus control women was
performed, a most interesting and statistically significant
reduction of inflammatory genes has been reported.[48]
The IL-15 pathway, known to play a key role in uterine NK
cell development and function, was identified at the center
of a pathway analysis and suppression of IL-15 by asoprisnil
was also observed on mRNA level. Furthermore, immunos-
taining for the uterine NK cell marker CD56 revealed an
impressive reduction in the asoprisnil-treated endometrium.
[48] In the normal cycling endometrium, IL-15 levels are
progesterone-responsive. In the study of asoprisnil-treated
endometrium, there is a downregulation of stromal PR
expression, upregulation of glandular PR expression (see
Figure 3), and a marked reduction in number of uterine NK
cells. These observations with administration of a SPRM have
provided support for a role for the IL-15 pathway in the
complex interplay between endometrial stromal cells, uter-
ine NK cells, and spiral arteries and an effect on both phy-
siological and HMB.[48,97,98]
4. Clinical potential for SPRMs in management of
benign gynecological disorders
Benign gynecological complaints such as HMB, fibroids, pelvic
pain, and endometriosis have a very significant impact on
quality of life and represent a large health-care burden. Each
year in the United Kingdom, one million women seek help for
HMB [99] and endometriosis has a prevalence of 2–10% of
women of reproductive age.[100] There are a multitude of
etiologies that can cause HMB.[101] Many cases have uterine
fibroids that disrupt everyday life and fibroids remain the
leading indication for hysterectomy.[102,103] While there
may be relief from HMB during pregnancy and lactation, and
an end to the problem at menopause, women affected will
tend to suffer the adverse impacts of HMB over what should
be the prime years of their lives. This can accumulate to a
lifetime loss of 5–7 years of ‘healthy’ life.
Along with the direct impact on the woman and her family,
there are significant costs both to the economy and the health
service. In the USA, lost work-hour costs are estimated
between $1.55 and 17.2 billion annually and direct costs of
$4.1–9.4 billion.[104]
Current medical therapies often either fail to fully resolve
symptoms or are associated with unacceptable side effects.
As a result, many women opt for a definitive solution
Figure 3. Image of progesterone receptor (PR) immuno-reactivity in human
endometrium after administration of a selective PR modulator (SPRM). Note
intense positive (brown) immunostaining in the glandular epithelium (g) and
virtual absence of immuno-reactivity in the stroma (s). Image kindly provided by
Professor Alistair Williams, University of Edinburgh. Full color available online.
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consequently hysterectomy remains the solution with the high-
est long-term patient satisfaction and cost-effectiveness.[99]
Many women however wish to avoid surgery and to retain
fertility. This is pertinent given that nearly half of all UK-born
babies are to women aged 30 or over.[105] Furthermore, those
from low-income backgrounds are less likely to receive a surgical
treatment [106] and as such may be further penalized by ineffec-
tive medical treatment. Finally, the recent RCOG HMB audit
reported that at 1-year post-referral only 35% of all women
(including those given surgery) were ‘satisfied’ (or better) at the
prospect of current menstrual symptoms continuing, as currently
experienced, for the next 5 years.[106] There is thus a very
substantial unmet need for long-term medical therapies that
are effective, affordable, and without unwanted side effects.
The evidence of the impact of SPRMs on endometrial cell
proliferation (reviewed above) and data from nonhuman pri-
mate studies have identified these compounds as offering
significant potential for longer term medical therapy of HMB.
Specifically, two members of this class, mifepristone and aso-
prisnil, have been shown to significantly reduce menstrual
blood loss in association with fibroids but do not increase
proliferation.[107,108] The impact of SPRM administration on
menstrual bleeding in women without fibroids is not known.
The medical management of endometriosis is currently lar-
gely dependent upon administration of progestogens and
estrogen deficiency has to date restricted long-term use of
GnRH analogs. With each of these commonly used therapies,
management is frequently limited by accompanying side
effects and symptom control may be suboptimal. Studies with
SPRM administration undertaken in women with endometriosis
indicate potential clinical utility for symptom relief.[109,110] For
example, mifepristone administration (50 mg for 6 months) in
patients with endometriosis has been reported to have a sig-
nificant effect on symptoms and extent of disease.[110] In a
randomized, placebo-controlled study, asoprisnil (5, 10, or
25 mg) was administered for 12 weeks to women with a
laparoscopic diagnosis of endometriosis who complained of
moderate or severe pain. A significant reduction in non-men-
strual pelvic pain and dysmenorrhea compared to placebo was
reported [111] that would be consistent with reports of a tissue-
specific suppression of endometrial prostaglandin production.
5. Conclusion
Studies on HMB are hampered by the lack of an appropriate in
vivo model for fibroid-associated endometrial bleeding limit-
ing our understanding of the interplay between fibroids and
endometrium.
At present, the biggest challenge facing researchers who
are keen to develop regimes using SPRMs as long-term treat-
ments for women with debilitating benign gynecological con-
ditions is a paucity of data related to the mechanisms
underpinning the development of PAEC.
6. Expert opinion
Progesterone acting via its cognate receptors (PR-A, PR-B)
plays a central role in regulation of uterine function making
PR an attractive therapeutic target.
PRs classical genomic mode of action has been studied in
detail and the impact of ligand binding, conformational
change, and coactivator and -repressor recruitment on cell
and tissue-specific patterns of gene expression is now better
understood.
The regulation/impact of non-genomic progesterone path-
ways has recently been described as via the trigger of SRC-
dependent phosphorylation signaling like proliferative RAS/
RAF/MEKK/MAPK kinase pathway. The level of interaction
and integration of these extranuclear signaling cascades with
classical genomic signaling remains a topic for further studies.
A number of SPRMs have been developed which have a
range of agonistic and antagonistic profiles when compared
with progesterone. Mechanistic studies have identified distinct
patterns of co-regulator recruitment that may in part explain
their unique impact on cell function. Here, more molecular
details will emerge in the future as the number of molecular
studies on human tissues will increase as more SPRMs enter
the market and it would be interesting to follow whether the
systematic analysis of expression profiles of different fibroid
and endometrial cellular components holds potential to gen-
erate a gene expression fingerprint which would be suitable to
allow differentiation of SPRMs on their mechanistic action
toward the different uterine cellular compartments.
Clinical studies indicate SPRMs hold promise for treatment
of fibroids and associated HMB. Extensive in vitro studies on
primary cells and small-scale investigations of biopsies from
clinical studies highlighted inhibition of cell proliferation and
an increase of the expression of proapoptotic markers and
pathways and suppression of extracellular matrix synthesis as
the molecular mechanism behind reduction of fibroid volume.
A link to progesterone action for fibroid growth has been
offered by identification of distinct leiomyoma stem-progeni-
tor cell populations processing paracrine signals from adjacent
myometrium induced by progesterone. One of the key com-
ponents mediating progesterone action in fibroid cells is the
WNT/β-catenin pathway. Dissecting the paracrine mechanism
involved with leiomyoma growth may also shed further light
into the molecular action of SPRMs and may also lead to new
treatments beyond SPRMs.
New fundamental insights into the etiology of fibroids will
arise from the latest development in research regarding the
MED12 mutation which is a driver mutation for fibroids with
very high prevalence rate. Very recently, MED12-mutant mice
have been generated, which will offer an opportunity to dis-
sect downstream signaling of Med12 and investigate effects
on tumor growth but also on AUB from adjacent endometrial
tissue. Whether potential factors might be identified causative
for induction of HMB will be an exciting area to follow.
In contrast to fibroid shrinkage, the cellular mechanisms by
which SPRMs control endometrial bleeding are still poorly
understood. Reduction in the numbers of uterine NK cells
and their complex interaction with the spiral arteries and
endometrial stroma cells maybe one possible explanation for
SPRMs’ effect on bleeding suppression.
The administration of the SPRM class of compound is
accompanied with morphological changes within the endo-
metrium described as PAEC. These histological changes are
recognized as a distinct histological entity and should not be
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confused with endometrial hyperplasia. However, whilst PAEC
are well described and appear reversible, a greater under-
standing of molecular and cellular mechanisms underpinning
these histological features is required.
Acknowledgments
We are most grateful to Mrs Sheila Milne for her help with manuscript
preparation and Mr Ronnie Grant for graphical assistance. We thank
Professor Alistair Williams, University of Edinburgh, for provision of the
histological image in Figure 3.
Declaration of interests
A Wagenfeld is an employee of Bayer Pharma Ag. H O. D. Critchley has acted
as a consultant for Bayer Pharma Ag, AbbVie Incorporated, Preglem SA,
Gedeon Ritcher, and Vifor Pharma Ag; and received research support from
Bayer Pharma Ag, Medical Research Council UK and the National Institute for
Health Research. P Saunders has received research support from Bayer
Pharma AG, and Medical Research Council UK. The authors have no other
relevant affiliations or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject matter or
materials discussed in the manuscript apart from those disclosed.
References
Papers of special note have been highlighted as:
• of interest
•• of considerable interest
1. Burney RO, Talbi S, Hamilton AE, et al. Gene expression analysis of
endometrium reveals progesterone resistance and candidate sus-
ceptibility genes in women with endometriosis. Endocrinology.
2007;148:3814–3826.
2. Salazar EL, Calzada L. The role of progesterone in endometrial
estradiol- and progesterone-receptor synthesis in women with
menstrual disorders and habitual abortion. Gynecol Endocrinol.
2007;23:222–225.
3. Maybin JA, Critchley HO. Progesterone: a pivotal hormone at men-
struation. Ann NY Acad Sci. 2011;1221:88–97.
4. Bulun SE. Uterine fibroids. N Engl J Med. 2013;369:1344–1355.
5. Li X, O’Malley BW. Unfolding the action of progesterone receptors.
J Biol Chem. 2003;278:39261–39264.
6. Patel B, Elguero S, Thakore S, et al. Role of nuclear progesterone
receptor isoforms in uterine pathophysiology. Hum Reprod Update.
2015;21:155–173.
7. Mani SK, Oyola MG. Progesterone signaling mechanisms in brain
and behavior. Front Endocrinol (Lausanne). 2012;3:7.
8. Obr AE, Edwards DP. The biology of progesterone receptor in the
normal mammary gland and in breast cancer. Mol Cell Endocrinol.
2012;357:4–17.
9. Maybin JA, Critchley HO. Menstrual physiology: implications for
endometrial pathology and beyond. Hum Reprod Update.
2015;21:748–761.
• Overview of endometrial biology in context of menstrual
bleeding and physiological progesterone withdrawal.
10. Brosens JJ, de Souza NM, Barker FG. Uterine junctional zone: func-
tion and disease. Lancet. 1995;346:558–560.
11. Fusi L, Cloke B, Brosens JJ. The uterine junctional zone. Best Pract
Res Clin Obstet Gynaecol. 2006;20:479–491.
12. Mote PA, Balleine RL, McGowan EM, et al. Heterogeneity of pro-
gesterone receptors A and B expression in human endometrial
glands and stroma. Hum Reprod. 2000;15(Suppl 3):48–56.
13. Critchley HO, Saunders PT. Hormone receptor dynamics in a recep-
tive human endometrium. Reprod Sci. 2009;16:191–199.
14. Mesiano S. Myometrial progesterone responsiveness. Semin
Reprod Med. 2007;25:5–13.
15. Lessey BA, Killam AP, Metzger DA, et al. Immunohistochemical
analysis of human uterine estrogen and progesterone receptors
throughout the menstrual cycle. J Clin Endocrinol Metab.
1988;67:334–340.
16. Ingamells S, Campbell IG, Anthony FW, et al. Endometrial proges-
terone receptor expression during the human menstrual cycle. J
Reprod Fertil. 1996;106:33–38.
17. Gellersen B, Brosens IA, Brosens JJ. Decidualization of the human
endometrium: mechanisms, functions, and clinical perspectives.
Semin Reprod Med. 2007;25:445–453.
• Overview of progesterone action on the endometrium.
18. Das SK. Cell cycle regulatory control for uterine stromal cell decid-
ualization in implantation. Reproduction. 2009;137:889–899.
19. Goddard LM, Murphy TJ, Org T, et al. Progesterone receptor in the
vascular endothelium triggers physiological uterine permeability
preimplantation. Cell. 2014;156:549–562.
20. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many
actors in search of a plot. Cell. 1995;83:851–857.
21. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear recep-
tor superfamily: the second decade. Cell. 1995;83:835–839.
22. Burris TP, Solt LA, Wang Y, et al. Nuclear receptors and their selective
pharmacologic modulators. Pharmacol Rev. 2013;65:710–778.
23. Pieber D, Allport VC, Bennett PR. Progesterone receptor isoform A
inhibits isoform B-mediated transactivation in human amnion. Eur J
Pharmacol. 2001;427:7–11.
24. Ellmann S, Sticht H, Thiel F, et al. Estrogen and progesterone
receptors: from molecular structures to clinical targets. Cell Mol
Life Sci. 2009;66:2405–2426.
25. Hagan CR, Knutson TP, Lange CA. A common docking domain in
progesterone receptor-B links DUSP6 and CK2 signaling to prolif-
erative transcriptional programs in breast cancer cells. Nucleic
Acids Res. 2013;41:8926–8942.
26. O’Malley BW. Coregulators: from whence came these “master
genes”. Mol Endocrinol. 2007;21:1009–1013.
27. Mangal RK, Wiehle RD, Poindexter AN 3rd, et al. Differential expres-
sion of uterine progesterone receptor forms A and B during the
menstrual cycle. J Steroid Biochem Mol Biol. 1997;63:195–202.
28. Wang H, Critchley HO, Kelly RW, et al. Progesterone receptor sub-
type B is differentially regulated in human endometrial stroma. Mol
Hum Reprod. 1998;4:407–412.
29. Kawaguchi K, Fujii S, Konishi I, et al. Immunohistochemical ana-
lysis of oestrogen receptors, progesterone receptors and Ki-67 in
leiomyoma and myometrium during the menstrual cycle and
pregnancy. Virchows Arch A Pathol Anat Histopathol.
1991;419:309–315.
30. Viville B, Charnock-Jones DS, Sharkey AM, et al. Distribution of the
A and B forms of the progesterone receptor messenger ribonucleic
acid and protein in uterine leiomyomata and adjacent myome-
trium. Hum Reprod. 1997;12:815–822.
31. Fujimoto J, Hirose R, Ichigo S, et al. Expression of progesterone
receptor form A and B mRNAs in uterine leiomyoma. Tumour Biol.
1998;19:126–131.
32. Bombail V, MacPherson S, Critchley HO, et al. Estrogen receptor
related beta is expressed in human endometrium throughout
the normal menstrual cycle. Hum Reprod. 2008;23:2782–2790.
33. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, et al. Subgroup of
reproductive functions of progesterone mediated by progesterone
receptor-B isoform. Science. 2000;289:1751–1754.
34. Conneely OM, Mulac-Jericevic B, Lydon JP, et al. Reproductive
functions of the progesterone receptor isoforms: lessons from
knock-out mice. Mol Cell Endocrinol. 2001;179:97–103.
35. Conneely OM, Mulac-Jericevic B, Lydon JP. Progesterone-
dependent regulation of female reproductive activity by two
distinct progesterone receptor isoforms. Steroids. 2003;68:771–
778.
36. Conneely OM, Mulac-Jericevic B, DeMayo F, et al. Reproductive
functions of progesterone receptors. Recent Prog Horm Res.
2002;57:339–355.
37. Samalecos A, Gellersen B. Systematic expression analysis and anti-
body screening do not support the existence of naturally occurring
8 A. WAGENFELD ET AL.
D
ow
nl
oa
de
d 
by
 [T
he
 U
niv
ers
ity
 of
 E
din
bu
rg
h]
 at
 03
:33
 17
 M
ay
 20
16
 
progesterone receptor (PR)-C, PR-M, or other truncated PR iso-
forms. Endocrinology. 2008;149:5872–5887.
38. Thomas P, Zhu Y, Pace M. Progestin membrane receptors involved
in the meiotic maturation of teleost oocytes: a review with some
new findings. Steroids. 2002;67:511–517.
39. Thomas P. Characteristics of membrane progestin receptor alpha
(mPRalpha) and progesterone membrane receptor component 1
(PGMRC1) and their roles in mediating rapid progestin actions.
Front Neuroendocrinol. 2008;29:292–312.
40. Hanna R, Pang Y, Thomas P, et al. Cell-surface expression, progestin
binding, and rapid nongenomic signaling of zebrafish membrane
progestin receptors alpha and beta in transfected cells. J
Endocrinol. 2006;190:247–260.
41. Krietsch T, Fernandes MS, Kero J, et al. Human homologs of the
putative G protein-coupled membrane progestin receptors
(mPRalpha, beta, and gamma) localize to the endoplasmic reticu-
lum and are not activated by progesterone. Mol Endocrinol.
2006;20:3146–3164.
42. Gellersen B, Fernandes MS, Brosens JJ. Non-genomic progesterone
actions in female reproduction. Hum Reprod Update. 2009;15:119–138.
43. Scarpin KM, Graham JD, Mote PA, et al. Progesterone action in
human tissues: regulation by progesterone receptor (PR) isoform
expression, nuclear positioning and coregulator expression. Nucl
Recept Signal. 2009;7:e009.
44. Liu Z, Auboeuf D, Wong J, et al. Coactivator/corepressor ratios
modulate PR-mediated transcription by the selective receptor
modulator RU486. Proc Natl Acad Sci U S A. 2002;99:7940–7944.
45. Han SJ, DeMayo FJ, Xu J, et al. Steroid receptor coactivator (SRC)-1
and SRC-3 differentially modulate tissue-specific activation func-
tions of the progesterone receptor. Mol Endocrinol. 2006;20:45–55.
46. Simmen RC, Heard ME, Simmen AM, et al. The Kruppel-like factors
in female reproductive system pathologies. J Mol Endocrinol.
2015;54:R89–R101.
47. Madauss KP, Grygielko ET, Deng SJ, et al. A structural and in vitro
characterization of asoprisnil: a selective progesterone receptor
modulator. Mol Endocrinol. 2007;21:1066–1081.
48. Wilkens J, Male V, Ghazal P, et al. Uterine NK cells regulate endo-
metrial bleeding in women and are suppressed by the progester-
one receptor modulator asoprisnil. J Immunol. 2013;191:2226–
2235.
49. Gregory CW, Wilson EM, Apparao KB, et al. Steroid receptor coacti-
vator expression throughout the menstrual cycle in normal and
abnormal endometrium. J Clin Endocrinol Metab. 2002;87:2960–
2966.
50. Gellersen B, Brosens J. Cyclic AMP and progesterone receptor cross-
talk in human endometrium: a decidualizing affair. J Endocrinol.
2003;178:357–372.
51. Kalkhoven E, Wissink S, van der Saag PT, et al. Negative interaction
between the RelA(p65) subunit of NF-kappaB and the progester-
one receptor. J Biol Chem. 1996;271:6217–6224.
52. Shatnawi A, Tran T, Ratnam M. R5020 and RU486 act as progester-
one receptor agonists to enhance Sp1/Sp4-dependent gene tran-
scription by an indirect mechanism. Mol Endocrinol. 2007;21:635–
650.
53. Hagan CR, Lange CA. Molecular determinants of context-depen-
dent progesterone receptor action in breast cancer. BMC Med.
2014;12:32.
54. Faus H, Haendler B. Post-translational modifications of steroid
receptors. Biomed Pharmacother. 2006;60:520–528.
55. Abdel-Hafiz HA, Horwitz KB. Post-translational modifications of the
progesterone receptors. J Steroid Biochem Mol Biol. 2014;140:80–
89.
56. Lange CA, Shen T, Horwitz KB. Phosphorylation of human proges-
terone receptors at serine-294 by mitogen-activated protein kinase
signals their degradation by the 26S proteasome. Proc Natl Acad
Sci U S A. 2000;97:1032–1037.
57. Chabbert-Buffet N, Meduri G, Bouchard P, et al. Selective proges-
terone receptor modulators and progesterone antagonists:
mechanisms of action and clinical applications. Hum Reprod
Update. 2005;11:293–307.
•• Overview of selective progesterone modulator (SPRM) field.
58. Boonyaratanakornkit V, McGowan E, Sherman L, et al. The role of
extranuclear signaling actions of progesterone receptor in mediat-
ing progesterone regulation of gene expression and the cell cycle.
Mol Endocrinol. 2007;21:359–375.
59. Cai W, Zhu Y, Furuya K, et al. Two different molecular mechanisms
underlying progesterone neuroprotection against ischemic brain
damage. Neuropharmacology. 2008;55:127–138.
60. Ballare C, Vallejo G, Vicent GP, et al. Progesterone signaling in breast
and endometrium. J Steroid Biochem Mol Biol. 2006;102:2–10.
61. Vares G, Sai S, Wang B, et al. Progesterone generates cancer stem
cells through membrane progesterone receptor-triggered signaling
in basal-like human mammary cells. Cancer Lett. 2015;362:167–173.
62. Lu J, Reese J, Zhou Y, et al. Progesterone-induced activation of
membrane-bound progesterone receptors in murine macrophage
cells. J Endocrinol. 2015;224:183–194.
63. Balasubramanian B, Portillo W, Reyna A, et al. Nonclassical mechan-
isms of progesterone action in the brain: I. Protein kinase C activa-
tion in the hypothalamus of female rats. Endocrinology.
2008;149:5509–5517.
64. Balasubramanian B, Portillo W, Reyna A, et al. Nonclassical mechan-
isms of progesterone action in the brain: II. Role of calmodulin-
dependent protein kinase II in progesterone-mediated signaling in
the hypothalamus of female rats. Endocrinology. 2008;149:5518–
5526.
65. Bashour NM, Wray S. Progesterone directly and rapidly inhibits
GnRH neuronal activity via progesterone receptor membrane com-
ponent 1. Endocrinology. 2012;153:4457–4469.
66. Vicent GP, Ballare C, Nacht AS, et al. Induction of progesterone
target genes requires activation of Erk and Msk kinases and phos-
phorylation of histone H3. Mol Cell. 2006;24:367–381.
67. Faivre E, Skildum A, Pierson-Mullany L, et al. Integration of proges-
terone receptor mediated rapid signaling and nuclear actions in
breast cancer cell models: role of mitogen-activated protein
kinases and cell cycle regulators. Steroids. 2005;70:418–426.
68. Madauss KP, Stewart EL, Williams SP. The evolution of progester-
one receptor ligands. Med Res Rev. 2007;27:374–400.
69. Lusher SJ, Raaijmakers HC, Vu-Pham D, et al. Structural basis for
agonism and antagonism for a set of chemically related progester-
one receptor modulators. J Biol Chem. 2011;286:35079–35086.
70. Chabbert-Buffet N, Pintiaux A, Bouchard P. The immninent dawn of
SPRMs in obstetrics and gynecology. Mol Cell Endocrinol.
2012;358:232–243.
71. Berrodin TJ, Jelinsky SA, Graciani N, et al. Novel progesterone
receptor modulators with gene selective and context-dependent
partial agonism. Biochem Pharmacol. 2009;77:204–215.
72. Wardell SE, Narayanan R, Weigel NL, et al. Partial agonist activity of
the progesterone receptor antagonist RU486 mediated by an
amino-terminal domain coactivator and phosphorylation of ser-
ine400. Mol Endocrinol. 2010;24:335–345.
73. Afhuppe W, Sommer A, Muller J, et al. Global gene expression
profiling of progesterone receptor modulators in T47D cells pro-
vides a new classification system. J Steroid Biochem Mol Biol.
2009;113:105–115.
74. Giangrande PH, Kimbrel EA, Edwards DP, et al. The opposing
transcriptional activities of the two isoforms of the human proges-
terone receptor are due to differential cofactor binding. Mol Cell
Biol. 2000;20:3102–3115.
75. Im A, Appleman LJ. Mifepristone: pharmacology and clinical impact
in reproductive medicine, endocrinology and oncology. Expert
Opin Pharmacother. 2010;11:481–488.
76. Hoellen F, Griesinger G, Bohlmann MK. Therapeutic drugs in the
treatment of symptomatic uterine fibroids. Expert Opin
Pharmacother. 2013;14:2079–2085.
77. Benagiano G, Bastianelli C, Farris M, et al. Selective progesterone
receptor modulators: an update. Expert Opin Pharmacother.
2014;15:1403–1415.
78. Yoshida S, Ohara N, Xu Q, et al. Cell-type specific actions of pro-
gesterone receptor modulators in the regulation of uterine leio-
myoma growth. Semin Reprod Med. 2010;28:260–273.
EXPERT OPINION ON THERAPEUTIC TARGETS 9
D
ow
nl
oa
de
d 
by
 [T
he
 U
niv
ers
ity
 of
 E
din
bu
rg
h]
 at
 03
:33
 17
 M
ay
 20
16
 
79. Horak P, Mara M, Dundr P, et al. Effect of a selective progesterone
receptor modulator on induction of apoptosis in uterine fibroids in
vivo. Int J Endocrinol. 2012;2012:436174.
80. Xu Q, Ohara N, Liu J, et al. Progesterone receptor modulator CDB-
2914 induces extracellular matrix metalloproteinase inducer in cul-
tured human uterine leiomyoma cells. Mol Hum Reprod.
2008;14:181–191.
81. Bulun SE, Moravek MB, Yin P, et al. Uterine leiomyoma stem cells:
linking progesterone to growth. Semin Reprod Med. 2015;33:357–
365.
82. Tanwar PS, Lee HJ, Zhang L, et al. Constitutive activation of Beta-
catenin in uterine stroma and smooth muscle leads to the develop-
ment of mesenchymal tumors in mice. Biol Reprod. 2009;81:545–552.
83. Mäkinen N, Mehine M, Tolvanen J, et al. MED12, the mediator
complex subunit 12 gene, is mutated at high frequency in uterine
leiomyomas. Science. 2011;334:252–255.
84. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endo-
metrial pathology induced by progesterone receptor modulators.
Mod Pathol. 2008;21:591–598.
•• Comprehensive description of PAEC (progesterone receptor
modulator associated endometrial changes).
85. Donnez J, Vazquez F, Tomaszewski J, et al. Long-term treatment of
uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101:1565–
1573.e18.
86. Esmya EMC 5 mg Tablets (ulipristal acetate). [cited 2016 Feb 2].
Available from: http://www.medicines.org.uk/emc/medicine/26068
87. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus
placebo for fibroid treatment before surgery. N Engl J Med.
2012;366:409–420.
88. Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate
versus leuprolide acetate for uterine fibroids. N Engl J Med.
2012;366:421–432.
89. Williams AR, Bergeron C, Barlow DH, et al. Endometrial morphology
after treatment of uterine fibroids with the selective progesterone
receptor modulator, ulipristal acetate. Int J Gynecol Pathol.
2012;31:556–569.
90. Attardi BJ, Burgenson J, Hild SA, et al. In vitro antiprogestational/
antiglucocorticoid activity and progestin and glucocorticoid recep-
tor binding of the putative metabolites and synthetic derivatives of
CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol.
2004;88:277–288.
91. Brenner RM, Slayden OD, Nath A, et al. Intrauterine administration
of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus
macaques. Contraception. 2010;81:336–342.
92. Pohl O, Williams AR, Bergeron C, et al. A 39-week oral toxicity study
of ulipristal acetate in cynomolgus monkeys. Regul Toxicol
Pharmacol. 2013;66:6–12.
93. Baird DT, Brown A, Critchley HO, et al. Effect of long-term treat-
ment with low-dose mifepristone on the endometrium. Hum
Reprod. 2003;18:61–68.
94. Slayden OD, Brenner RM. Hormonal regulation and localization
of estrogen, progestin and androgen receptors in the endome-
trium of nonhuman primates: effects of progesterone receptor
antagonists. Arch Histol Cytol. 2004;67:393–409.
95. Brenner RM, Slayden OD. Progesterone receptor antagonists and
the endometrial antiproliferative effect. Semin Reprod Med.
2005;23:74–81.
96. Williams AR, Critchley HO, Osei J, et al. The effects of the selective
progesterone receptor modulator asoprisnil on the morphology of
uterine tissues after 3 months treatment in patients with sympto-
matic uterine leiomyomata. Hum Reprod. 2007;22:1696–1704.
97. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a
diagnostic marker for the earliest endometrial precancers. J Natl
Cancer Inst. 2000;92:924–930.
98. Wilkens J, Williams AR, Chwalisz K, et al. Effect of asoprisnil on
uterine proliferation markers and endometrial expression of
the tumour suppressor gene, PTEN. Hum Reprod. 2009;24:1036–
1044.
99. NICE. Clinical Guideline 44; Heavy menstrual bleeding 2007; [cited
2016 Feb 2]. Available from: http://www.nice.org.uk/nicemedia/
pdf/CG44FullGuideline.pdf
100. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet
Gynecol Clin North Am. 1997;24:235–258.
101. Munro MG, Critchley HO, Broder MS, et al. FIGO classification
system (PALM-COEIN) for causes of abnormal uterine bleeding in
nongravid women of reproductive age. Int J Gynaecol Obstet.
2011;113:3–13.
• Classification of AUB (abnormal uterine bleeding) aimed to
ensure comprehensive classification of underpinning etiolo-
gies to facilitate clinical care and fundamental research.
102. Stewart EA. Uterine fibroids. Lancet. 2001;357:293–298.
103. Merrill RM. Hysterectomy surveillance in the United States, 1997
through 2005. Med Sci Monit. 2008;14:CR24–CR31.
104. Cardozo ER, Clark AD, Banks NK, et al. The estimated annual cost of
uterine leiomyomata in the United States. Am J Obstet Gynecol.
2012;206:211.e1–211.e9.
105. ONS. Who is having babies? 2009; [cited 2016 Feb 2]. Available
from: http://webarchive.nationalarchives.gov.uk/20140721132900/
http://www.statistics.gov.uk/pdfdir/births1209.pdf
106. RCOG. National heavy menstrual bleeding audit final report.
London: RCOG; 2014.
107. Engman M, Granberg S, Williams AR, et al. Mifepristone for treat-
ment of uterine leiomyoma. A prospective randomized placebo
controlled trial. Hum Reprod. 2009;24:1870–1879.
108. Wilkens J, Chwalisz K, Han C, et al. Effects of the selective proges-
terone receptor modulator asoprisnil on uterine artery blood flow,
ovarian activity, and clinical symptoms in patients with uterine
leiomyomata scheduled for hysterectomy. J Clin Endocrinol
Metab. 2008;93:4664–4671.
109. Chwalisz K, Garg R, Brenner RM, et al. Selective progesterone
receptor modulators (SPRMs): a novel therapeutic concept in endo-
metriosis. Ann N Y Acad Sci. 2002;955:373–388.
110. Kettel LM, Murphy AA, Morales AJ, et al. Treatment of endometrio-
sis with the antiprogesterone mifepristone (RU486). Fertil Steril.
1996;65:23–28.
111. Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone
receptor modulator development and use in the treatment of
leiomyomata and endometriosis. Endocr Rev. 2005;26:423–438.
10 A. WAGENFELD ET AL.
D
ow
nl
oa
de
d 
by
 [T
he
 U
niv
ers
ity
 of
 E
din
bu
rg
h]
 at
 03
:33
 17
 M
ay
 20
16
 
